Drug Trial Radar · NCT04535531
A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
Last checked: Nov 19, 2026Latest source record: Jan 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
891
Actual
Start
Sep 1, 2020
Primary completion
Apr 28, 2021
Study completion Jul 28, 2021
Sponsor
- Lead sponsor
- Novan, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Therapeutics, Inc.; Synteract, Inc.
- First posted
- Sep 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 850 subjects 6 months of age and older with molluscum contagiosum (MC). Subjects or their caregivers will apply SB206 10.3% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.
Conditions
- Molluscum Contagiosum
Interventions
SB206 10.3% berdazimerDrug
Topically once daily
vehicle gelDrug
Topically once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Clearance of All Treatable MC at Week 12Time frame: 12 Weeks
Locations
55 sites in 1 country. Site status is shown where the registry gives one.
Site #312
Glendale, Arizona
Site #101
Hot Springs, Arkansas
Site #272
Rogers, Arkansas
Site #336
Fountain Valley, California
Site #329
Fremont, California
Site# 348
Fresno, California
Site #161
San Diego, California
Site #327
Thousand Oaks, California
Site #325
Greenwood Village, Colorado
Site #335
Apopka, Florida
Site #342
Boca Raton, Florida
Site #333
Fort Lauderdale, Florida
Site #334
Homestead, Florida
Site #278
Miami, Florida
Site #314
Miami Lakes, Florida
Site #341
Orlando, Florida
Site #227
Sanford, Florida
Site #305
Tampa, Florida
Site #116
Newnan, Georgia
Site #340
Chicago, Illinois
Site #253
Rolling Meadows, Illinois
Site #288
Evansville, Indiana
Site #310
Plainfield, Indiana
Site #328
Bowling Green, Kentucky
Site #347
Lexington, Kentucky
Site # 117
Louisville, Kentucky
Site #294
Owensboro, Kentucky
Site #321
Baton Rouge, Louisiana
Site# 349
Covington, Louisiana
Site #332
New Orleans, Louisiana
Site #297
New Orleans, Louisiana
Site #330
Rockville, Maryland
Site #346
Brighton, Massachusetts
Site #274
Clarkston, Michigan
Site #121
New Brighton, Minnesota
Site #338
Omaha, Nebraska
Site #201
Berlin, New Jersey
Site #331
Verona, New Jersey
Site #279
Greensboro, North Carolina
Site #250
Portland, Oregon
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.